ABSTRACT
A case of diffuse and recidivant alveolar hemorrhage is presented in a patient with hepatitis C virus-related type II mixed cryoglobulinemia with membranoproliferative glomerulonephritis. The patient was a 48-year-old white woman who suffered several outbreaks of pulmonary hemorrhage refractory to treatment with steroids, cyclophosphamide, azathioprine, plasmapheresis and interferon-alpha. The patient also presented persistent increased titers of immune complexes and rheumatoid factor with no histological hepatic alterations. Some considerations about evolution and treatment are given according to the updated physiopathology of this disease.
Subject(s)
Cryoglobulinemia/complications , Glomerulonephritis, Membranoproliferative/complications , Hemorrhage/etiology , Hepatitis C/complications , Lung Diseases/etiology , Pulmonary Alveoli , Cryoglobulinemia/blood , Cryoglobulinemia/therapy , Fatal Outcome , Female , Glomerulonephritis, Membranoproliferative/blood , Glomerulonephritis, Membranoproliferative/therapy , Hemorrhage/pathology , Hemorrhage/therapy , Hepatitis C/blood , Hepatitis C/therapy , Humans , Lung Diseases/pathology , Lung Diseases/therapy , Middle AgedSubject(s)
Acute Kidney Injury/etiology , Embolism/complications , Renal Artery , Aged , Cholesterol , Crystallization , Embolism/etiology , Humans , Male , Time FactorsABSTRACT
The analysed clinico-biological manifestations, evolutive course and treatment of 30 patients with GCA are presented. The most frequent symptoms were fever and headache. 33% of patients had FOD criteria. 26% had various visual alterations. All patients were initially treated with steroids. Of the 26 patients followed up, 21 (81.7%) experienced some sort of complication: Cushing iatrogenic, osteoporosis, vertebrae collapse, aseptic necrosis of the femur head, arterial hypertension, diabetes mellitus, hyperlipidemia, steroid myopathy. 6 patients were treated with cyclophosphamide, following severe complications secondary to steroid therapy, and all of them had a good clinical evolution.